Close

Johnson & Johnson to test single-shot coronavirus vaccine on 60,000 people in phase-3 trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

NHS Boards to Explore Joint Working...

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients...

The NHS in England has remained under relentless pressure...

Thermo Fisher Receives FDA Approval for...

The world leader when it comes to serving science,...

Virtual MRI Imaging with AI Aids...

During the magnetic resonance imaging (MRI) procedures, contrast agents...

Pharmaceutical giant Johnson & Johnson (J&J) has begun the phase-three trials of its single-shot coronavirus vaccine candidate, the company announced on September 23.

The fourth experimental vaccine to enter the last stage of trials in the United States will recruit up to 60,000 adult volunteers in the US and other countries to determine its safety and effectiveness.

Unlike the three vaccines developed by Moderna, Pfizer and BioNTech, and AstraZeneca and the University of Oxford, that require a re-visit and second shot three to four weeks after the first one to trigger a protective immune response, J&J will be initially testing a single dose.

Besides, J&J vaccine can also be stored in liquid form at refrigerator temperatures for three months, whereas two of the front-runner candidates must be frozen or kept at ultracold temperatures for long-term storage.

“A single-shot vaccine, if it’s safe and effective, will have substantial logistic advantages for global pandemic control,” said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, who partnered with J&J to develop the vaccine told Washington Post.

Latest stories

Related stories

NHS Boards to Explore Joint Working in Sussex and Surrey

In a recent update, two NHS boards to explore...

NHS Performance Standards Tested as Patients Volume Grows

The NHS in England has remained under relentless pressure...

Virtual MRI Imaging with AI Aids Better Tumor Detection

During the magnetic resonance imaging (MRI) procedures, contrast agents...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back